Factors associated with severe versus mild immunotherapy-related systemic reactions: A case-referent study

Liss, Gary M.; Murphy-Berendts, Karen; Epstein, Tolly; Bernstein, David I.

doi:10.1016/j.jaci.2010.12.1086

Cited by 9 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sani et al (25) showed a higher rate of systemic reactions in patients treated with dog/cat or dust mite allergens. Similarly, Liss et al (24) higher doses of dust mite extract were associated with an increased frequency of mild systemic reactions. On the other hand, Dursun et al (15) found no difference between allergen extracts used for immunotherapy in terms of local or systemic reactions.…”

Section: Discussionmentioning

confidence: 85%

“…Barth et al (22) reported a systemic reaction incidence of 0.2% and 0.5% in patients receiving mono-allergen or multiple-allergen immunotherapy, respectively. In some previous studies focusing on SCIT, the allergen extracts used for immunotherapy were also proposed to have an association with local or systemic adverse effects (24,25). Sani et al (25) showed a higher rate of systemic reactions in patients treated with dog/cat or dust mite allergens.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Local and Systemic Reactions due to Subcutaneous Allergen Immunotherapy: Our Single-Center 5-Year Experience

Aytekin¹,

Yıldız

Çölkesen

et al. 2022

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

Objective: Subcutaneous allergen immunotherapy (SCIT) currently represents the only disease-modifying therapeutic option for the treatment of allergic rhinitis/conjunctivitis, asthma, and venom sensitization. Although SCIT represents a fairly safe therapeutic option in the hands of experienced physicians and canters, it may also be associated with certain adverse effects. In this study, we describe the local and systemic adverse effects in our adult patients undergoing immunotherapy over a 5-year period in an effort to define the causative factors. Material and Methods:A total of 4413 injections administered to 119 patients (58 female, 61 male) were analysed.Results: A total of 119 patients with a mean age of 33.7±12 years were included (Female: 58, 48%; Male: 61, 51.3%). In the total population of 119 patients, 6 (5%) developed local reactions, 21 (17.7%) developed large local reactions, and 9 (7.6%) had systemic reactions. Of all injections administered throughout the study period, 0.14% were associated with local reactions, 0.48% with large local reactions, and 0.20% with systemic reactions. Four patients with systemic reactions (44.4%) required epinephrine injection. Patients who did or did not develop adverse effects were significantly different with regard to IgE levels and eosinophil counts (p=0.001 and p=0.002). There was a significant difference between the rates of total adverse reactions developing during the build-up or maintenance phase (p=0.025). Conclusion:Clinicians' awareness regarding the local, large local, and systemic reactions associated with SCIT should be improved, and clinicians should be more careful during the immunotherapy, especially in the build-up phase, for adverse events.

show abstract

Section: Discussionmentioning

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Local and Systemic Reactions due to Subcutaneous Allergen Immunotherapy: Our Single-Center 5-Year Experience

Aytekin¹,

Yıldız

Çölkesen

et al. 2022

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi

View full text Add to dashboard Cite

show abstract

Immunotherapy Safety: What Have We Learned from Surveillance Surveys?

Kannan

Epstein

2013

Curr Allergy Asthma Rep

View full text Add to dashboard Cite

Subcutaneous allergen immunotherapy (SCIT) is beneficial for the treatment of allergic rhinitis, asthma, and in preventing stinging insect anaphylaxis, but is not without risks. Four retrospective surveillance surveys and one on-going national prospective study have attempted to characterize the incidence and risk factors for fatal and non-fatal SCIT reactions. These studies have contributed significantly to currently recommended SCIT safety guidelines. Recent surveillance studies indicate stable SR rates, and a possible decline in the incidence of fatal reactions since the implementation of evidence-based safety guidelines. This review will provide a detailed summary of the evidence from surveillance studies for risk factors associated with SCIT reactions, including: uncontrolled asthma, prior systemic reactions, dosing during peak pollen seasons, epinephrine being delayed or not given, dosing or administration errors, inadequate waiting times, reactions occurring more than 30 min after injections, injections given in medically unsupervised settings, concomitant beta-blocker and angiotensin-converting enzyme inhibitor (ACEi) use, and accelerated build-up regimens.

show abstract

Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy–year 2

Epstein

Liss

Murphy-Berendts

et al. 2011

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

show abstract

Factors associated with severe versus mild immunotherapy-related systemic reactions: A case-referent study

Cited by 9 publications

References 11 publications

Local and Systemic Reactions due to Subcutaneous Allergen Immunotherapy: Our Single-Center 5-Year Experience

Local and Systemic Reactions due to Subcutaneous Allergen Immunotherapy: Our Single-Center 5-Year Experience

Immunotherapy Safety: What Have We Learned from Surveillance Surveys?

Immediate and delayed-onset systemic reactions after subcutaneous immunotherapy injections: ACAAI/AAAAI surveillance study of subcutaneous immunotherapy–year 2

Contact Info

Product

Resources

About